An interventional study of Sebacia Microparticles in Facial Acne Vulgaris, sponsored by Sebacia, Inc.. Completed at 3 sites in 2 countries. Open to participants aged 16 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-09-07.
Sponsored by Sebacia, Inc. · Not applicable, Interventional, and Treatment
This study is proposed to evaluate Sebacia Microparticle treatment in patients with facial inflammatory acne vulgaris.
730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.
This study's enrollment of 85 is above the median of 69 across 628 interventional studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →Sebacia, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Sebacia Microparticles
Percent reduction in lesion count from baseline
Time frame: Baseline, Week 12, Week 24, Week 36
Improvement in Investigator Global Acne Score
Time frame: Baseline, Week 12, Week 24, Week 36
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sebacia, Inc.